SOP’s Mattingly Awarded $2.2 Million Grant to Investigate Bulk Drug Substances for Compounding
December 4, 2018
Grant from the U.S. Food and Drug Administration will span three years and include evaluations for more than 200 nominated substances.
FDA
M-CERSI Cooperative Agreement Grant Renewed by Food and Drug Administration
October 3, 2018
Latest renewal allows for up to $5 million per year over five years, and will help M-CERSI further advance its mission to promote the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.
CTM, FDA Collaborate to Assess Extrapolation of Anti-Epileptic Drugs’ Effectiveness
March 24, 2016
FDA praises the Center’s efforts to bring academic, government, and industry stakeholders together for collaborative project with wide-reaching implications.
School of Pharmacy Sees Unparalleled Growth in Research Funding
December 7, 2015
New grants and contracts from a multitude of non-profit and government organizations, as well as the private sector, help the School of Pharmacy achieve the highest funding increase among all professional and graduate schools at the University of Maryland, Baltimore.
CERSI Symposium Highlights Use of Biomarkers in Drug Development
August 28, 2015
More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.
SOP’s Polli Testifies for GDUFA Renewal at National Public Meeting
August 6, 2015
Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).
SOP Faculty Receive $1.5 Million from the FDA to Study Iron Medications
February 24, 2015
Interdisciplinary group will research the effectiveness of brand versus generic iron medications used to treat anemia in kidney disease patients